Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer
Open Access
|Nov 2012References
- 1. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.2004;23-30.
- 2. Arevalo Lobera S, Sagastibeltza Marinelarena N, Elejoste Echeberria I, Mele Olive M, Egana Otano L, Basterretxea Badiola L, et al. Fatal pneumonitis induced by oxaliplatin.2008;764-7.
- 3. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma.2009;1-8.
- 4. Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, et al. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis.2011;285-91.
- 5. Jung KH, Kil SY, Choi IK, Seo JH, Shin C, Kim YS, et al. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).2006;1181-2.
- 6. Mundt P, Mochmann HC, Ebhardt H, Zeitz M, Duchmann R, Pauschinger M. Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer.2007;270-2.
- 7. Park S, Jung JJ, Kim GB, Yoon HS, Ko SH, Ko JE, et al. Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin.2010;340-3.
- 8. Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.2001;243-5.
- 9. Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy.2007;50-7.
- 10. Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.2005;832-7.
- 11. Lami L, Areces F, Lence JJ, Arbesu MA. FOLFOX-4 Regimen as a first-line therapy for cuban patients with metastatic colorectal cancer.2009;34-8.
- 12. Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, et al. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study.2009;1346-53.
- 13. Lim JH, Kim H, Choi WG, Lee MH. Interstitial lung disease associated with FOLFOX chemotherapy.2010;546-8.
- 14. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Hatakeyama K. Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX).2009;457-9.
- 15. Pena Alvarez C, Suh Oh HJ, Saenz de Miera Rodriguez A, Garcia Arroyo FR, Covela Rua M, Salgado Boquete L, et al. Interstitial lung disease associated with oxaliplatin: description of two cases.2009;332-3.
- 16. Dahlqvist C, Fremault A, Carrasco J, Colinet B. Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy.2010;84-7.
- 17. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.2011;2005-10.
- 18. Velenik V. Post-treatment surveillance in colorectal cancer.2010;135-41.
Language: English
Page range: 360 - 362
Submitted on: Oct 18, 2011
Accepted on: Nov 7, 2011
Published on: Nov 9, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2012 Liam M Hannan, Jaclyn Yoong, Geoffrey Chong, Christine F Mcdonald, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.